Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

αB-crystallin: a novel regulator of breast cancer metastasis to the brain.

Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie K, Hamilton E, Blackwell K, Geradts J, Ewend M, Carey L, Shusta EV, Anders CK, Cryns VL.

Clin Cancer Res. 2014 Jan 1;20(1):56-67. doi: 10.1158/1078-0432.CCR-13-1255. Epub 2013 Oct 16.

2.

αB-crystallin expression is correlated with phospho-ERK1/2 expression in human breast cancer.

van de Schootbrugge C, van Asten F, Nagtegaal ID, Versleijen-Jonkers YM, van Laarhoven HW, Roeffen MH, Sweep FC, Bussink J, Kaanders JH, Pruijn GJ, Boelens WC, Span PN.

Int J Biol Markers. 2013 Dec 17;28(4):e365-70. doi: 10.5301/jbm.5000032.

PMID:
23722303
3.

ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo.

Malin D, Strekalova E, Petrovic V, Rajanala H, Sharma B, Ugolkov A, Gradishar WJ, Cryns VL.

Oncogene. 2015 Nov 5;34(45):5626-34. doi: 10.1038/onc.2015.12. Epub 2015 Feb 16.

4.

Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain.

Avraham HK, Jiang S, Fu Y, Nakshatri H, Ovadia H, Avraham S.

J Pathol. 2014 Feb;232(3):369-81. doi: 10.1002/path.4304.

PMID:
24421076
5.

αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis.

Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, Minn AJ, Cryns VL, Cheang MC.

NPJ Breast Cancer. 2015 Oct 21;1. pii: 15014.

6.

E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.

Chen HA, Chang YW, Tseng CF, Chiu CF, Hong CC, Wang W, Wang MY, Hsiao M, Ma JT, Chen CH, Jiang SS, Wu CH, Hung MC, Huang MT, Su JL.

Ann Surg Oncol. 2015 Mar;22(3):889-98. doi: 10.1245/s10434-014-4061-3. Epub 2014 Sep 12. Erratum in: Ann Surg Oncol. 2017 Feb 3;:.

PMID:
25212833
7.

AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.

Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK.

Ann Diagn Pathol. 2008 Feb;12(1):33-40. doi: 10.1016/j.anndiagpath.2007.02.004. Epub 2007 Oct 24.

PMID:
18164413
8.

AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.

Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, Cryns VL.

J Clin Invest. 2006 Jan;116(1):261-70.

9.

alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.

Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, Memmel HC, Rademaker A, Gradishar WJ, Morrow M, Khan SA, Cryns VL.

Breast Cancer Res Treat. 2008 Oct;111(3):411-7. Epub 2007 Oct 30.

PMID:
17968656
10.

αB-Crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer.

Kim HS, Lee Y, Lim YA, Kang HJ, Kim LS.

J Breast Cancer. 2011 Mar;14(1):14-9. doi: 10.4048/jbc.2011.14.1.14. Epub 2011 Mar 31.

11.

PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.

Paul A, Gunewardena S, Stecklein SR, Saha B, Parelkar N, Danley M, Rajendran G, Home P, Ray S, Jokar I, Vielhauer GA, Jensen RA, Tawfik O, Paul S.

Cell Death Differ. 2014 Sep;21(9):1469-81. doi: 10.1038/cdd.2014.62. Epub 2014 May 2.

12.

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.

Koletsa T, Stavridi F, Bobos M, Kostopoulos I, Kotoula V, Eleftheraki AG, Konstantopoulou I, Papadimitriou C, Batistatou A, Gogas H, Koutras A, Skarlos DV, Pentheroudakis G, Efstratiou I, Pectasides D, Fountzilas G.

BMC Clin Pathol. 2014 Jun 23;14:28. doi: 10.1186/1472-6890-14-28. eCollection 2014.

13.

Discovery of structure-based small molecular inhibitor of αB-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo.

Chen Z, Ruan Q, Han S, Xi L, Jiang W, Jiang H, Ostrov DA, Cai J.

Breast Cancer Res Treat. 2014 May;145(1):45-59. doi: 10.1007/s10549-014-2940-8. Epub 2014 Apr 8.

PMID:
24710637
14.

Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.

Xiang L, Gilkes DM, Chaturvedi P, Luo W, Hu H, Takano N, Liang H, Semenza GL.

J Mol Med (Berl). 2014 Feb;92(2):151-64. doi: 10.1007/s00109-013-1102-5. Epub 2013 Nov 20.

15.

Cancer-associated fibroblast promote transmigration through endothelial brain cells in three-dimensional in vitro models.

Choi YP, Lee JH, Gao MQ, Kim BG, Kang S, Kim SH, Cho NH.

Int J Cancer. 2014 Nov 1;135(9):2024-33. doi: 10.1002/ijc.28848. Epub 2014 Mar 28.

16.

αB-crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation.

Petrovic V, Malin D, Cryns VL.

Breast Cancer Res Treat. 2013 Apr;138(2):415-25. doi: 10.1007/s10549-013-2465-6. Epub 2013 Mar 8.

17.

Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).

Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, Lin C, Zhan Q, Qian H, Xu B.

Cancer Lett. 2014 Oct 28;353(2):153-9. doi: 10.1016/j.canlet.2014.06.022. Epub 2014 Aug 14.

PMID:
25130168
18.

Regulation of alphaB-crystallin gene expression by the transcription factor Ets1 in breast cancer.

Bosman JD, Yehiely F, Evans JR, Cryns VL.

Breast Cancer Res Treat. 2010 Jan;119(1):63-70. doi: 10.1007/s10549-009-0330-4. Epub 2009 Feb 11.

19.

Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade.

Choy C, Raytis JL, Smith DD, Duenas M, Neman J, Jandial R, Lew MW.

Oncol Rep. 2016 Jun;35(6):3135-42. doi: 10.3892/or.2016.4710. Epub 2016 Mar 28.

20.

S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.

Ehmsen S, Hansen LT, Bak M, Brasch-Andersen C, Ditzel HJ, Leth-Larsen R.

Int J Cancer. 2015 Nov 1;137(9):2093-103. doi: 10.1002/ijc.29582. Epub 2015 May 21.

Supplemental Content

Support Center